For decades, companies have been able to determine on their own, often with outside expert panels, that a novel ingredient is generally recognized as safe without ever filing with FDA. A rule requiring mandatory agency submission would end that shortcut and route every new ingredient decision through a federal review process that is already stretched thin. Experts questioning whether FDA has the staff and budget to handle the volume are raising a fair point, and the practical effect for brand owners could be longer waits before a new ingredient, novel delivery format, or reformulated blend can go to market.
This matters most for anyone planning innovation around emerging actives, functional food ingredients, or specialty extracts that haven't already cleared FDA review. Brands relying on established, already-recognized ingredients have less to worry about in the near term. But product roadmaps built around cutting-edge inputs should build in more lead time now. A manufacturing partner with regulatory experience and flexible formulation options can help brands adjust sourcing and launch timing if this pathway actually changes.